Trial reportProceedings of the National Academy of Sciences of the United States of America2012
Efficacy of vaccination with recombinant vaccinia and fowlpox vectors expressing NY-ESO-1 antigen in ovarian cancer and melanoma patients.
Trial report in Proceedings of the National Academy of Sciences of the United States of America, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 107 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
107 citing papers in PubMed, 1 synthesis or guideline pooled it, 195 citations in OpenAlex.
- Antigen-specific active immunotherapy for ovarian cancer.The Cochrane database of systematic reviews · 2018Pooled it
- Checkpoint immunotherapy is associated with preferential activation of tumor antigen-specific CD4Blood neoplasia · 2025Trial
- Safety, immunogenicity, and clinical efficacy of durvalumab in combination with folate receptor alpha vaccine TPIV200 in patients with advanced ovarian cancer: a phase II trial.Journal for immunotherapy of cancer · 2020Trial
- Low-dose cyclophosphamide enhances antigen-specific CD4(+) T cell responses to NY-ESO-1/ISCOMATRIX™ vaccine in patients with advanced melanoma.Cancer immunology, immunotherapy : CII · 2015Trial
- Immunological data from cancer patients treated with Ad5/3-E2F-Δ24-GMCSF suggests utility for tumor immunotherapy.Oncotarget · 2015Trial
- Biopsies Can Predict Lung Adenocarcinoma IASLC Grade: A New Proposal and Grading Pitfalls.JTO clinical and research reports · 2026Article
- Review
- Predicting Durable Anti-tumor Immune Responses after Cancer Vaccines.Journal of cancer immunology · 2026Article
- mTOR inhibition modulates vaccine-induced immune responses to generate memory T cells in patients with solid tumors.Journal for immunotherapy of cancer · 2025Article
- Magnitude of antigen-specific T-cell immunity the month after completing vaccination series predicts the development of long-term persistence of antitumor immune response.Journal for immunotherapy of cancer · 2024Article
- NY-ESO-1 antigen: A promising frontier in cancer immunotherapy.Clinical and translational medicine · 2024Review
- Tumor targeting peptide TMTP1 modified Antigen capture Nano-vaccine combined with chemotherapy and PD-L1 blockade effectively inhibits growth of ovarian cancer.Journal of nanobiotechnology · 2024Article
- The potential value of cancer-testis antigens in ovarian cancer: Prognostic markers and targets for immunotherapy.Immunity, inflammation and disease · 2024Review
- Mass Spectrometry-Based Proteomics of Epithelial Ovarian Cancers: A Clinical Perspective.Molecular & cellular proteomics : MCP · 2023Review
- Immunotherapeutic Approaches in Ovarian Cancer.Current issues in molecular biology · 2023Review
- Current advances in cancer vaccines targeting NY-ESO-1 for solid cancer treatment.Frontiers in immunology · 2023Review
- Immunotherapy in Ovarian Cancer.Archivum immunologiae et therapiae experimentalis · 2022Review
- Review
- Myeloid antigen-presenting cell niches sustain antitumor T cells and license PD-1 blockade via CD28 costimulation.Cancer cell · 2021Article
- A prime/boost vaccine platform efficiently identifies CD27 agonism and depletion of myeloid-derived suppressor cells as therapies that rationally combine with checkpoint blockade in ovarian cancer.Cancer immunology, immunotherapy : CII · 2021Article
47 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors at 6 institutions in 2 countries.
Funding
Abstract
Recombinant poxviruses (vaccinia and fowlpox) expressing tumor-associated antigens are currently being evaluated in clinical trials as cancer vaccines to induce tumor-specific immune responses that will improve clinical outcome. To test whether a diversified prime and boost regimen targeting NY-ESO-1 will result in clinical benefit, we conducted two parallel phase II clinical trials of recombinant vaccinia-NY-ESO-1 (rV-NY-ESO-1), followed by booster vaccinations with recombinant fowlpox-NY-ESO-1 (rF-NY-ESO-1) in 25 melanoma and 22 epithelial ovarian cancer (EOC) patients with advanced disease who were at high risk for recurrence/progression. Integrated NY-ESO-1-specific antibody and CD4(+) and CD8(+) T cells were induced in a high proportion of melanoma and EOC patients. In melanoma patients, objective response rate [complete and partial response (CR+PR)] was 14%, mixed response was 5%, and disease stabilization was 52%, amounting to a clinical benefit rate (CBR) of 72% in melanoma patients. The median PFS in the melanoma patients was 9 mo (range, 0-84 mo) and the median OS was 48 mo (range, 3-106 mo). In EOC patients, the median PFS was 21 mo (95% CI, 16-29 mo), and median OS was 48 mo (CI, not estimable). CD8(+) T cells derived from vaccinated patients were shown to lyse NY-ESO-1-expressing tumor targets. These data provide preliminary evidence of clinically meaningful benefit for diversified prime and boost recombinant pox-viral-based vaccines in melanoma and ovarian cancer and support further evaluation of this approach in these patient populations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.